|
|
Blood, 15 September 2006, Vol. 108, No. 6, pp. 2106-2113.
Prepublished online as a Blood First Edition Paper on June 6, 2006; DOI 10.1182/blood-2006-03-007427.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions
Ronjon Chakraverty,
Hyeon-Seok Eom,
Jessica Sachs,
Jennifer Buchli,
Pete Cotter,
Richard Hsu,
Guiling Zhao, and
Megan Sykes
From the Transplantation Biology Research Center, Bone Marrow Transplantation Section, Massachusetts General Hospital/Harvard Medical School, Boston.
Following bone marrow transplantation, delayed donor leukocyte infusions (DLIs) can induce graft-versus-leukemia (GVL) effects without graft-versus-host disease (GVHD). These antitumor responses are maximized by the presence of host hematopoietic antigen-presenting cells (APCs) at the time of DLI. Using a tumor-protection model, we demonstrate here that GVL activity following administration of DLIs to established mixed chimeras is dependent primarily on reactivity to allogeneic MHC antigens rather than minor histocompatibility or tumor-associated antigens. CD8+ T-cell–dependent GVL responses against an MHC class II–negative tumor following delayed DLI require CD4+ T-cell help and are reduced significantly when host APCs lack MHC class II expression. CD4+ T cells primed by host APCs were required for maximal expansion of graft-versus-host reactive CD8+ T cells but not their synthesis of IFN- . In contrast, the GVL requirement for CD4+ T-cell help was bypassed almost completely when DLI was administered to freshly irradiated recipients, indicating that the host environment is a major factor influencing the cellular mechanisms of GVL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y. Kamiryo, M. Eto, H. Yamada, T. Yajima, M. Harano, A. Takeuchi, K. Tatsugami, M. Hamaguchi, S. Naito, and Y. Yoshikai
Donor CD4 T Cells Are Critical in Allogeneic Stem Cell Transplantation against Murine Solid Tumor
Cancer Res.,
June 15, 2009;
69(12):
5151 - 5158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ghosh, W. Koestner, M. Hapke, V. Schlaphoff, F. Langer, R. Baumann, C. Koenecke, M. Cornberg, K. Welte, B. R. Blazar, et al.
Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras
Blood,
April 30, 2009;
113(18):
4440 - 4448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-J. Kolb
Graft-versus-leukemia effects of transplantation and donor lymphocytes
Blood,
December 1, 2008;
112(12):
4371 - 4383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Chakraverty, B. Flutter, F. Fallah-Arani, H.-S. Eom, T. Means, G. Andreola, S. Schwarte, J. Buchli, P. Cotter, G. Zhao, et al.
The Host Environment Regulates the Function of CD8+ Graft-versus-Host-Reactive Effector Cells
J. Immunol.,
November 15, 2008;
181(10):
6820 - 6828.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Chakraverty and M. Sykes
The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia
Blood,
July 1, 2007;
110(1):
9 - 17.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Durakovic, V. Radojcic, M. Skarica, K. B. Bezak, J. D. Powell, E. J. Fuchs, and L. Luznik
Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse
Blood,
May 15, 2007;
109(10):
4564 - 4574.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
